Board of Directors

Martin J. Murphy, DMedSc, PhD, FASCO

Chairman & Co-Founder

Dr_Martin_J_MurphyAt the request of the 41st President George H.W. Bush, Martin J. Murphy, DMedSc, PhD, FASCO, became the Founding CEO and Board Director of the non-profit CEO Roundtable on Cancer. He served as CEO for two decades, before becoming its Director Emeritus in 2021. Marty was also founding CEO of Project Data Sphere®, a non-profit initiative of the CEO Roundtable devoted to cancer clinical trial data-sharing and analysis. He is founder and CEO of the non-profit Shanghai TuoXin Health Promotion Center, which has expanded its purview from cancer prevention and improving cancer patient outcomes to include international Covid-19 interventions and global pandemic preparedness

Founding Executive Editor of the peer-reviewed journal, THE ONCOLOGIST®, Marty is also Founding Editor of  STEM CELLS®, the flagship journal of stem cell biology, and co-founder of its sister journal, STEM CELLS TRANSLATIONAL MEDICINE®, which reports on stem cells in clinical trials. He co-chairs the Scientific & Strategic Advisory Council of the International COVID-19 Data Alliance at the request of the Bill & Melinda Gates Foundation.

A former NIH principal investigator, Marty has authored more than 180 primary peer-accepted papers and seven books, is co-founder and chairman of Society for Translational Oncology, member of six Scientific Advisory Boards, two corporate boards of directors, Chairman Emeritus of Conquer Cancer—ASCO Foundation, and Steering Member of Chinese Society of Clinical Oncology. In 2021, he became Director Emeritus of the CEO Roundtable on Cancer. He is an Emeritus Member of National Cancer Policy Forum of National Academy of Medicine (US National Academy of Sciences), board member of Center for Public Health Advisory Board of the Milken Institute, Director Emeritus of Foundation for NIH, Fellow of American Society of Clinical Oncology, and former vice chairman of C-Change.

Marty is married to Ann Murphy, PhD, President and Founder of AlphaMed Press and Co-founder and Executive Director of Society for Translational Oncology. They have five adult children and ten grandchildren.

Kenneth B. Lee, Jr., MBA


Kenneth B. Lee, Jr.Kenneth B. Lee, Jr., MBA, is a general partner of Hatteras Ventures Partners, LLC, a venture capital fund focusing on life science companies. Ken is the former co-head of the International Life Sciences Practice for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the EY’s national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these firms included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

Ken has served on the Board of Directors 10 publicly held life sciences companies, including CV Therapeutics, Abgenix, Maxygen, OSI, Inspire Pharmaceuticals, and Biocryst, among others. He also served on the boards of several privately-held life sciences companies.

Ken served as CFO and interim CEO of the CEO Roundtable on Cancer, a not-for-profit organization founded by George H. W. Bush, Dr. Martin J. Murphy, and Robert Ingram. He also served on the Boards of the UNC Health Foundation and of NCBIO.

Ken graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.

Ann Murphy, PhD

Executive Director & Co-Founder

Ann MurphyAnn Murphy, PhD, is the Executive Director of the Society for Translational Oncology (STO). She has served on the board of STO for over two decades, working closely with other board members to identify the needs of oncology and hematology practitioners and steering STO to create and implement strategies and programs to enhance care for cancer patients and others with weakened immune systems.

Ann is also the President and CEO of AlphaMed Press. Under Ann’s leadership, AlphaMed Press founded three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines: THE ONCOLOGIST® (1996), devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care; STEM CELLS® (1983), the world's first journal devoted to this fast-paced field of research; and STEM CELLS TRANSLATIONAL MEDICINE® (2011), bridging stem cell research and clinical trials. In January 2022, these three journals were entrusted, via acquisition, to Oxford University Press (OUP).

Ann’s community and philanthropic board engagements include membership on University of North Carolina-Chapel Hill Board of Visitors.

Sean Khozin, MD, MPH

Independent Director

Sean KhozinSean Khozin, MD, MPH, is a Senior Life Sciences and Healthcare Partner at Braven. He is a physician-executive, board certified oncologist, and data scientist who is globally recognized as a leader in drug development, regulation, and applications of artificial intelligence and machine learning in biomedical research and therapeutic development.

Prior to joining Braven, an early-stage investor that co-builds breakthroughs in large, regulated sectors – finance, healthcare, and industrials, Sean was the Chief Executive Officer of CancerLinQ, a precision oncology enterprise focused on transforming cancer care and research with real-world data and advanced analytics. He was formerly the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative new medicines and vaccines.

He also was a founding member of the US FDA’s Oncology Center of Excellence and Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that he established under special federal authorities. As a uniquely entrepreneurial sandbox housed within the agency responsible for regulating nearly a third of the US economy, INFORMED played a pivotal role in shaping the US FDA’s position on real-world evidence and catalyzing the use of novel data science solutions in drug discovery and clinical development.

Before his tenure in the US federal government, Sean was the cofounder of Hello Health, a technology company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical systems for optimizing patient care and clinical research. The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics he had founded called SKMD.

Sean is a Research Affiliate at the MIT Laboratory for Financial Engineering, where he combines his quantitative and life sciences expertise in support of novel financing strategies for improving the lives of patients with cancer. He has over a decade of clinical and basic science research experience at the US National Cancer Institute and currently serves on the boards of Alliance for Artificial Intelligence in Healthcare and the Digital Medicine Society.

Ke Liu, MD, PhD

Independent Director

Ke LiuKe Liu, MD, PhD, is Chief Development Officer of Marengo Therapeutics. Ke has over 20 years of experience in the field of oncology, immuno-oncology, and cell and gene therapy, most recently serving as Senior Vice President and leading key regulatory activities at Sana Biotechnology. Prior to Sana, he spent more than 17 years working at the U.S. Food and Drug Administration (FDA) where he held leadership roles at the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and the Oncology Center of Excellence (OCE). Ke has made major contributions to the field of oncology and led the clinical evaluations and approvals of key first-in-class cancer therapeutics over the past decade, including checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) modified T cells, genome-edited products, neoantigen-based therapies, adoptive T cell therapies, oncolytic viral therapy, dendritic cell therapy, and combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other agents.

Ke received his MD from Henan Medical University in China and his Ph.D. in molecular biology from Cornell University. He completed his internal medicine internship and residency at Albert Einstein College of Medicine, his medical oncology fellowship at the National Cancer Institute (NCI), and additional cancer immunotherapy training at the NCI’s Surgery Branch. Ke is an internist and medical oncologist certified by the American Board of Internal Medicine.

Mace L. Rothenberg, MD, FACP

Independent Director

Mace L. Rothenberg, MDMace L. Rothenberg, MD, FACP, is a physician-executive with more than 30 years of experience in drug development, translational research, and risk-benefit assessment.

Mace served as Chief Medical Officer of Pfizer from 2019 to 2021. Prior to that role, Mace was Pfizer’s Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016, and Chief Development Officer for Oncology from 2016 to 2018. During that time, his organization developed and obtained regulatory approval for 11 new cancer medicines including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer.

Prior to joining Pfizer, Mace was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, he was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.

Mace is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society and the Statesman Award from the American Society of Clinical Oncology. He is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Mace serves on the Board of Directors for Aulos Bioscience, Tango Therapeutics, and Surrozen. He also serves on the boards of several non-profit organizations including the Vanderbilt University School of Medicine Basic Sciences, the Vanderbilt-Ingram Cancer Center, Nashville Biosciences, and Society for Translational Oncology.

Mace received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982. He received his post-graduate training in Internal Medicine at the Vanderbilt University Medical Center and in Medical Oncology at the National Cancer Institute.

Lillian L. Siu, MD, FRCPC, FASCO

Independent Director

Liilian SiuLillian L Siu, MD, FRCPC, FASCO, is senior medical oncologist at Princess Margaret Cancer Centre since 1998 and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Lillian served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016) and on the AACR Board of Directors for a three-year term (2017-2020).

Lillian’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the co-Contact Principal Investigator of a phase I cooperative agreement UM1 award sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution's core vision to deliver precision cancer medicine.

Internationally, Lillian was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She has been awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs.

Lillian has published over 370 peer-reviewed manuscripts and is currently Editor-in-Chief of the journal Cancer Research Communications, and is on the editorial board for JAMA Oncology, Cell and Cancer Cell.

Lillian was a founding faculty member of Advanced Clinical Trial training in China (ACT-China). A collaboration between STO and the Chinese Society for Clinical Oncology (CSCO), leaders of ASCO and the European Medicines Agency (EMA) provided both tutelage and encouragement that helped train a generation of China’s rising stars in oncology who are now conducting cancer clinical trials.

After earning her medical degree at the University of Toronto, Lillian completed her fellowship at Princess Margaret Cancer Centre, and completed drug development fellowships at Princess Margaret Cancer Centre and the University of Texas Science Center San Antonio.

View the Mission Advisory Board

Privacy Policy | Terms of Use | Contact Us

Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.